WOCKPHARMA Wockhardt Ltd Product Launches Announcement 2025 - New Drug Efficacy Wockhardt Ltd. announced that its drug Zaynich (WCK 5222) has achieved over 97% efficacy in a clinical study for treating serious infections caused by Meropenem-resistant gram-negative pathogens..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd